Wills Robert James's Form 4 filing
Oncternal Therapeutics, Inc. (ONCT) · filed Feb 27, 2024
- Accession no.
- 0001209191-24-004015
- Filed
- Feb 27, 2024
- Trade date
- Feb 23, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $8.86K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Wills Robert JamesCIK 0001634189 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 23, 2024 | Common Stock | SSaleDisposed | −980 | $9.04F1 | −$8,859.2 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The shares of common stock were sold directly to another director of the Issuer, David F. Hale, and an affiliated entity of Mr. Hale in a private sale. The price per share was based on the closing price of the Issuer's common stock on February 23, 2024.
Referenced by the price of 1 transaction in Table I.
Remarks
The number of shares of common stock in this form have been adjusted to reflect the Issuer's 1-for-20 reverse stock split effective as of January 8, 2024.